Cardio-Oncology Education and Training: JACC Council Perspectives
- PMID: 33153587
- PMCID: PMC8174559
- DOI: 10.1016/j.jacc.2020.08.079
Cardio-Oncology Education and Training: JACC Council Perspectives
Abstract
The innovative development of cancer therapies has led to an unprecedented improvement in survival outcomes and a wide array of treatment-related toxicities, including those that are cardiovascular in nature. Aging of the population further adds to the number of patients being treated for cancer, especially those with comorbidities. Such pre-existing and developing cardiovascular diseases pose some of the greatest risks of morbidity and mortality in patients with cancer. Addressing the complex cardiovascular needs of these patients has become increasingly important, resulting in an imperative for an intersecting discipline: cardio-oncology. Over the past decade, there has been a remarkable rise of cardio-oncology clinics and service lines. This development, however, has occurred in a vacuum of standard practice and training guidelines, although these are being actively pursued. In this council perspective document, the authors delineate the scope of practice in cardio-oncology and the proposed training requirements, as well as the necessary core competencies. This document also serves as a roadmap toward confirming cardio-oncology as a subspecialty in medicine.
Keywords: cancer; cardio-oncology; cardiotoxicity; training.
Copyright © 2020. Published by Elsevier Inc.
Conflict of interest statement
Author Relationship With Industry Dr. Zaha is supported by The Cancer Prevention Research Institute of Texas award RP18040. Dr. Mitchell is supported by the Children’s Discovery Institute and Longer Life Foundation. Dr. Herrmann is supported by the National Institutes of Health/National Cancer Institute grant R01CA233601 and the Miami/Florida Heart Research Foundation. Dr. Mitchell has received research funds from Pfizer. Dr. Barac has been on the advisory board of Takeda Ariad Pharmaceuticals. Dr. Dent has grant funding from Novartis US; and has received consultant fees from Novartis Canada. Dr. Lenihan has been a consultant to Lilly, Acorda, Bristol Myers Squibb, and Roche; and has received research funding from Myocardial Solutions. Dr. Herrmann has been a consultant to Amgen, Bristol Myers Squibb, and Takeda (Ariad) Pharmaceuticals. None of these are directly related to the current work.
Figures
References
-
- McCune JS. Rapid advances in immunotherapy to treat cancer. Clin Pharmacol Ther 2018;103: 540–4. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34. - PubMed
-
- Lenihan DJ, Cardinale D, Cipolla CM. The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis 2010; 53:88–93. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
